Europe encompasses approximately 50 countries that feature cultural, linguistic, economic, and geographic diversity. The 28 member states of the European Union each present unique opportunities and challenges for international research collaboration.
This region faces local disease burdens such as tuberculosis, vector-borne illnesses, and tickborne infections, as well as newly emerging health risks such as chikungunya virus and dengue. New cases of HIV infection present a growing problem in Eastern Europe, where the primary mode of transmission is among people who inject drugs, according to the Joint United Nations Programme on HIV/AIDS.
This region also presents opportunities for research on immunological conditions such as peanut allergy, which continues to emerge in the United Kingdom despite public health measures to discourage peanut exposure during infancy. European researchers are part of the Immune Tolerance Network, an international consortium co-sponsored by NIAID that is dedicated to the clinical evaluation of new tolerance-inducing therapies for autoimmune diseases, asthma and allergic diseases, and transplant rejection.
NIAID priorities for this region include research on HIV/AIDS, mosquito-borne illnesses, influenza, and basic immunology.
- Czech Republic
- United Kingdom
"New Frontiers in Antibacterial Resistance" Workshop, January 20-21, 2016, Stockholm, Sweden
The goals of this workshop included discussing cutting-edge approaches to address antibacterial resistance; fostering communication and research collaborations among scientists in the United States and the European Union; and sharing information on funding opportunities to advance antibacterial resistance research.
TUBITAK-NIAID/NIH Scientific Workshop on Genetically-Based Immune Disorders, October 15-17, 2014, Ankara, Turkey
Goals for this workshop included sharing information about research on genetically linked human immune dysregulatory disorders; initiating new and expanding upon current collaborations focused on genetically based immune diseases; identifying potential participants for these collaborations; and developing plans and proposals that will lead to concrete research cooperation and the expansion of research capacity focused on genetically based immune disease.